A subset of EGFR-mutant, MET-amplified lung cancers relies only on MET activation for survival Sep. 15, 2021
Tempest Therapeutics licenses intellectual property to cancer target from University of California Sep. 14, 2021
Discovery of apigenin derivative with potential to overcome drug-resistant MET-mutant RCC Sep. 14, 2021
RSS